Proglumide

Proglumide is a drug that functions as a cholecystokinin antagonist, which is used primarily in the treatment of gastrointestinal disorders and certain types of cancer. It was first synthesized in the 1970s and has been used in various medical applications since then.

History

Proglumide was first synthesized in the 1970s by a team of researchers at the University of Florence in Italy. The drug was initially developed as a treatment for peptic ulcer disease, but its use has since expanded to include other gastrointestinal disorders and certain types of cancer.

Pharmacology

Proglumide works by blocking the action of the hormone cholecystokinin (CCK), which is involved in the regulation of gastrointestinal motility and pancreatic enzyme secretion. By inhibiting the action of CCK, proglumide can reduce the symptoms of conditions such as gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS).

Medical uses

Proglumide is used primarily in the treatment of gastrointestinal disorders, including peptic ulcer disease, GERD, and IBS. It can also be used to treat certain types of cancer, such as pancreatic cancer, by inhibiting the growth of cancer cells.

Side effects

Like all drugs, proglumide can cause side effects. These can include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, proglumide can cause more serious side effects, such as liver damage or allergic reactions.

See also

• Cholecystokinin antagonist
• Gastrointestinal disorders
• Pancreatic cancer